Skip to main content
OpenTrials
Completed

NCT Number: NCT02527629

Aortic Replacement Using Individualised Regenerative Allografts - ARISE (the "Surveillance")

Evaluation of decellularized human heart valves for aortic heart valve replacement in comparison to current valve substitutes.

Safety endpoints include cardiovascular adverse events, time to re-operation, re-intervention and explantation.

Efficacy endpoints include freedom from valve dysfunction and hemodynamic performance.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Universitair Ziekenhuis Leuven, UZL, Leuven, Belgium

Loading trial locations.

About this study

This is a prospective, non-randomized, single-arm, multi-centre surveillance study to be conducted in Europe.

The Surveillance is designed as a study, where

  • ARISE AV is prescribed in the usual manner in accordance with the terms of the approval.
  • Assignment of the patient to a particular therapeutic strategy is not decided in advance by this Surveillance Protocol but falls within current practice and the prescription of ARISE AV is clearly separated from the decision to include the patient in the Surveillance.
  • No additional diagnostic or monitoring procedures shall be applied to the patients.
  • and epidemiological methods shall be used for the analysis of collected data.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

i. Indication for aortic valve replacement according to current medical guidelines in valvular heart disease

ii. Informed consent of legal guardians or patients, assent of patients

Exclusion criteria

i. The patient has not provided Surveillance informed consent.

ii. The patient shall not suffer from:

  • generalized connective tissue disorders (eg, Marfan syndrome), or .
  • active rheumatic disorders, or
  • severe asymmetric calcification of the valve ring.

iii. The coronary arteries of the patient shall not be in abnormal position or heavily calcified.

iv. Patients shall not show hypersensitivity against sodium dodecyl sulphate (SDS), sodium desoxycholate (SDC), human collagen (or other elastic fibers) or Benzonase®.

Treatment and study plan

Decellularized human heart valves

Other

Decellularized human aortic heart valves

Other names: Arise Aortic Valve (AV)

Primary outcomes

  1. Cardiovascular Adverse Reactions (AR)

    Time frame: up to 24 months

    Rate of cardiovascular AR, e.g. all-cause mortality, major stroke, life-threatening (or disabling) bleeding, acute kidney injury-stage 3 (including renal replacement therapy), peri-procedural myocardial infarction, major vascular complication, repeat procedure for valve-related dysfunction (surgical or interventional therapy).

  2. Freedom from valve dysfunction at end of the study

    Time frame: up to 24 months

    Echocardiographic studies should be obtained and analyzed at discharge and at 3, 6 Months and at annual follow-ups. The requested variables include peak and mean systolic gradient, using pw and cw doppler, in the left ventricular outflow tract, respective the aortic valve. The echo evaluation (videotape or CD) should remain at the Surveillance site, but be available to corlife Surveillance personnel upon request. The MRIs will be analyzed by the MRI Core Laboratory at Medical School in Hannover for potential valvular stenosis, via phase contrast flow measurements in the aorta and for valvular competence, via phase contrast flow measurements and by ventricular volumetry. MRI cine images will be used to visualize the Surveillance valve in patients with poor echocardiographic windows.

Secondary outcomes

  1. Evaluation of composite blood parameters

    Time frame: up to 24 months

    The following data should be collected: Hb, LDH, Haptoglobin, CRP, Leukocytes. Blood studies should be performed within 7 days preoperatively and at discharge. Blood data will support the absence/presence of related AR. For example, haemolysis should be reported as an adverse event if anaemia is present; however, in the absence of anaemia, haemolysis will be considered to be compensated and does not require reporting. Time to events, such as death, reoperation including explantation will be evaluated for those outcomes, calculated from the date of operation.

  2. Time to reoperation and / or death

    Time frame: up to 24 months

    Time to events, such as death, reoperation including explantation will be evaluated for those outcomes, calculated from the date of operation

  3. Evaluation of composite valve measures

    Time frame: up to 24 months

    Diameters of ARISE AV at end of the Surveillance will be analyzed in comparison to diameters at implantation and to age matched reference values. Preoperative non-invasive data on left ventricular size and function, such as left ventricular end diastolic, end systolic volume, ejection fraction and ventricular mass will be derived from MRI and compared to postoperative status.

Sponsors and collaborators

Lead sponsor

corlife

Industry

Collaborators

  • Azienda Ospedaliera di Padova
  • Hannover Medical School
  • Heinrich-Heine University, Duesseldorf
  • Hospital Clinic of Barcelona
  • Leiden University Medical Center
  • Royal Brompton & Harefield NHS Foundation Trust
  • Universitaire Ziekenhuizen KU Leuven
  • Vienna General Hospital

Registry information

Official study title

Aortic Replacement Using Individualised Regenerative Allografts: Bridging the Therapeutic Gap - ARISE (the "Surveillance")

Acronym: ARISE

Important dates

Study start
2015
Primary completion
2019
Study completion
2019
First posted
Aug 19, 2015
Registry last updated
Jun 2, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.